SPOTLIGHT: Avastin leaves ASCO ahead of Erbitux


Shares of Genentech have been buoyed by news from ASCO that Avastin will likely be preferred to Erbitux for treating lung cancer. Avastin offers an extra month of average survival time compared to Erbitux. Report

Suggested Articles

In this week's EuroBiotech Report, Roche's risdiplam clears another phase 3 SMA trial, Merck KGaA spinout raises cash and Korean VCs back PDC*line.

In our EuroBiotech roundup this week, a liver disease biotech raises €11 million, Autolus offers stock and Abivax plans midphase trial. 

Merck KGaA spinout iOnctura has raised a €15 million series A round to support an early-phase solid tumor trial of a PI3Kδ inhibitor.